Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global market for psoriasis medications is expected to expand from USD 22.36 billion in 2025 to USD 32.98 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.69%. These drugs are specialized pharmaceutical products designed to manage psoriasis, an ongoing autoimmune disease characterized by skin inflammation. Market expansion is largely driven by the rising incidence of this condition worldwide, alongside ongoing developments in targeted biologics and innovative small-molecule treatments that deliver better results for patients. Additionally, greater public awareness and improved diagnostic tools are increasing the number of individuals pursuing medical care. As noted in the 2025 Global Psoriasis Atlas (Third Edition) by the International Federation of Psoriasis Associations (IFPA), roughly 43 million people globally have been officially diagnosed with psoriasis by a medical professional.

In spite of these positive trends, the high expenses linked to cutting-edge biologic therapies present a major obstacle to the market's continued growth. Such steep financial requirements create significant hurdles for patients and medical systems worldwide, which can restrict widespread use and market reach. This issue is particularly pronounced in areas where healthcare funding is limited, ultimately preventing broader access to these advanced treatments.

Market Driver

The rising worldwide occurrence of psoriasis is a primary catalyst for the growth of the psoriasis drugs market, as a broader patient demographic requires effective therapeutic options. This escalating disease burden drives the need for both traditional and innovative medications. Highlighting this trend, a November 2025 global analysis by HCPLive revealed that the age-standardized incidence rate for men with psoriasis increased by 10.3% from 1990 to 2021, illustrating a steady climb in new diagnoses. The continuous growth in both new cases and the total patient population guarantees ongoing demand for medical treatments, spanning from topical creams to complex systemic therapies, which ultimately fuels market expansion.

At the same time, ongoing breakthroughs in biologic and targeted treatments are deeply impacting the industry by delivering enhanced effectiveness and better health outcomes for patients. These scientific steps forward resolve historically unmet medical needs and broaden the range of available therapies. Illustrating this progress, the National Psoriasis Foundation reported in December 2025 that long-term findings for the TYK2 inhibitor deucravacitinib showed 70% of users sustaining a Psoriasis Area Severity Index score of 75 for five years, confirming lasting clinical value. The development and successful rollout of such sophisticated therapies significantly boost the market's total worth, as evidenced by Fierce Pharma's October 2025 report noting that the leading biologic Skyrizi generated USD 4.7 billion in third-quarter sales, a remarkable 47% increase from the previous year.

Market Challenge

A primary obstacle restraining the global psoriasis drugs market's expansion is the steep price tag tied to modern biologic treatments. These exorbitant costs act as a major roadblock to market growth, actively restricting patient access and wider adoption, especially in areas with limited healthcare funding. Consequently, the heavy economic strain frequently stops both individuals and healthcare providers from utilizing these highly capable therapies, even with their proven ability to deliver superior health results.

The premium pricing of biologics creates substantial barriers to acquiring care. Highlighting this issue, a December 2025 retrospective cohort study in Clinical Dermatology found that 15.5% of individuals faced hurdles when starting biologic therapies, mostly resulting from insurance rejections or coverage gaps. This reality directly stifles market progression by lowering the adoption rate of cutting-edge medications, since financial limitations frequently overshadow the medical advantages for numerous prospective patients worldwide. Furthermore, the need for sustained, long-term therapy worsens the economic pressure, leading to interrupted or uninitiated treatment plans, which ultimately limits overall market capacity and revenue potential.

Market Trends

The introduction of innovative oral small-molecule medications is fundamentally transforming the global psoriasis drugs sector by giving patients easier alternatives to conventional injectable therapies. This evolution meets a vital demand for less intrusive delivery methods, which can boost treatment compliance and enhance the general patient experience.

These drugs offer clear benefits for those wanting potent systemic care without the hassle of needles, ultimately broadening the population of eligible patients and shifting how doctors prescribe medications. As an example, beginning in January 2026, Bristol Myers Squibb will make its oral TYK2 inhibitor, deucravacitinib (Sotyktu), available via the BMS Patient Connect system for USD 950 monthly to qualified individuals, marking roughly an 86% reduction from the standard list price. This approach to pricing significantly improves drug availability and encourages the use of these pioneering oral therapies.

At the same time, the growing acceptance of biosimilar medications has become a crucial market trend, especially for offsetting the steep prices of sophisticated biologic therapies. By fostering market competition, biosimilars help lower costs and improve financial accessibility, granting more patients the ability to use effective treatments that were once too expensive.

This broadened access is essential for international healthcare systems attempting to balance fiscal constraints with the goal of delivering better patient results. Highlighting this impact, an April 10, 2025, FirstWord Pharma press release detailed a Sandoz-backed study titled 'IMKASID 2025: Study Shows Ustekinumab Biosimilars Could Save €526 Million Across European Markets,' which projected three-year savings of €526 million across Germany, the United Kingdom, and Sweden due to ustekinumab biosimilars. The rollout of these budget-friendly substitutes is driving a highly competitive environment and facilitating deeper market penetration for psoriasis treatments.

Key Market Players

• AbbVie Inc.
• Johnson & Johnson
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• UCB S.A.
• Bristol Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Almirall, S.A.
• Boehringer Ingelheim International GmbH

Report Scope

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

• Biologic Drugs
• Small Molecule Systemic Drugs
• Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

• TNF Alpha Inhibitors
• PDE4 Inhibitors
• Interleukin Inhibitors
• Others

Psoriasis Drugs Market, By Route of Administration:

• Oral
• Parenteral
• Topical

Psoriasis Drugs Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.